DSM Biologics and MorphoSys to manufacture fully human antibody

Published: 15-Aug-2008
Manufacturing

DSM Biologics and MorphoSys have signed a biopharmaceutical manufacturing agreement covering process development and cGMP manufacturing of MOR202.


DSM Biologics and MorphoSys have signed a biopharmaceutical manufacturing agreement covering process development and cGMP manufacturing of MOR202.

MOR202 is a fully human HuCAL antibody directed against CD38, a promising target for the treatment of multiple myeloma. DSM Biologics will manufacture MOR202 in its cGMP facilities in Groningen, the Netherlands. Further financial details were not disclosed.

"Based on the positive experiences we have gained with the PER.C6 cell line and DSM's manufacturing capabilities within our MOR103 lead programme, we have chosen to continue to use this platform for MOR202," said Dr Marlies Sproll, chief scientific officer of MorphoSys.

See more

You may also like

Manufacturing

dsm-firmenich initiates patent infringement action

Read more
dsm-firmenich asserts that Shengda’s production of a key biotin intermediate at its Anhui site is an unlawful use of patented technology

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

dsm-firmenich initiates patent infringement action

dsm-firmenich asserts that Shengda’s production of a key biotin intermediate at its Anhui site is an unlawful use of patented technology
Manufacturing

DSM and Chromatic 3D Materials partner

The global science-based company active in health, nutrition and materials, has entered a partnership with the 3D-printer developer to introduce thermoset materials for 3D-printing of finished manufactured goods
Manufacturing

DSM Sinochem to boost manufacturing capacity at Dutch plant

Increased production will meet growing demand for sustainable antibiotics, helping tackle Antimicrobial Resistance
Manufacturing

DSM Sinochem Pharmaceuticals celebrates 15 years of green 7-ADCA production

Saving more than lives alone
Manufacturing

Update on SafeBridge potent compound safety certification programme

The programme provides drug innovators with an independent assessment of a manufacturing company’s ability to safely produce potent APIs and drug products
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

The impact of API properties on product design

Different properties of active ingredients can affect formulation design and development decisions. Dr Anil Kane, Patheon, and Dr Kai Donsbach, DSM Fine Chemicals Austria, look at some of the key properties
Manufacturing

JLL and Royal DSM create DPx from US$2.6bn joint venture

New global CDMO combines capabilities and expertise of Patheon and DSM Pharmaceutical Products
Subscribe now